JAMES WEHMEIER: Open Payments
NPI 1992417059 · COLUMBIA, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$269 in 11 payments from 7 companies in 2025. Trend: 2023 $649 · 2024 $895 · 2025 $269
Food & beverage: $269
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 1 | $78 |
| ABBVIE INC. | 4 | $77 |
| Novo Nordisk Inc | 2 | $33 |
| LivaNova USA, Inc. | 1 | $28 |
| GlaxoSmithKline, LLC. | 1 | $18 |
| Merz Pharmaceuticals, LLC | 1 | $18 |
| Lilly USA, LLC | 1 | $17 |
Products named: Symbravo, UBRELVY, QULIPTA, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, SHINGRIX, Ozempic, Xeomin, JARDIANCE.
Industry payments across MO — which companies pay providers there.
